Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P61086

UPID:
UBE2K_HUMAN

ALTERNATIVE NAMES:
E2 ubiquitin-conjugating enzyme K; Huntingtin-interacting protein 2; Ubiquitin carrier protein; Ubiquitin-conjugating enzyme E2-25 kDa; Ubiquitin-protein ligase

ALTERNATIVE UPACC:
P61086; A6NJC1; A8K5Y9; B2RDF8; C9JGP1; O54806; P27924; Q16721; Q9CVV9; Q9Y2D3

BACKGROUND:
The Ubiquitin-conjugating enzyme E2 K, known for interacting with huntingtin and participating in the ubiquitination and proteolytic processing of NF-kappa-B, is a key player in the ubiquitin-proteasome system. It mediates the synthesis of 'Lys-48'-linked polyubiquitin chains, crucial for the selective degradation of proteins, including the suppression of apoptosis in lipid-bearing macrophages and the degradation of p53/TP53. Its involvement in viral infections, such as the cytomegalovirus-induced degradation of MHC class I heavy chains, underscores its versatile role in cellular defense mechanisms.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Ubiquitin-conjugating enzyme E2 K could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.